MRI Abdomen with Contrast

Contrast-enhanced abdominal MRI provides superior soft-tissue contrast and multiphase characterization of hepatic, pancreatic, biliary, renal, and adrenal pathology without ionizing radiation. Chemical-shift imaging, diffusion, and dynamic gadolinium phases enable lesion detection and specific characterization such as fat, fibrosis, and vascularity. MRCP non-invasively depicts the biliary and pancreatic ducts. It is the problem-solving tool of choice following equivocal ultrasound or CT.

Indications

Detection and characterization of focal liver lesions (hemangioma, FNH, adenoma, HCC, metastases)
Chronic liver disease surveillance and HCC characterization using hepatobiliary or extracellular agents
MRCP for choledocholithiasis, biliary strictures, and pancreatic ductal anatomy
Characterization of pancreatic masses, cystic lesions, and pancreatitis complications
Indeterminate renal masses and characterization of complex cysts
Adrenal lesion characterization (adenoma vs non-adenoma) via chemical-shift imaging
Assessment of iron and fat content in diffuse liver disease
Problem-solving of indeterminate CT/ultrasound findings and staging of abdominal malignancy

Contraindications & Cautions

Non-MRI-conditional implanted devices and ferromagnetic foreign bodies
Severe renal impairment (eGFR <30) restricts gadolinium; use macrocyclic agents and weigh risk of nephrogenic systemic fibrosis
Gadolinium hypersensitivity
Pregnancy: avoid gadolinium; non-contrast MRI/MRCP is preferred when imaging is essential
Inability to breath-hold degrades dynamic imaging; consider free-breathing/radial techniques
Severe claustrophobia

Patient Preparation

MRI safety screening for devices and implants
Fast 4-6 hours to reduce bowel motion, empty the stomach, and improve MRCP by minimizing fluid overlap
Administer negative oral contrast (e.g., pineapple/blueberry juice) to suppress overlapping GI fluid for MRCP
Check eGFR and obtain contrast consent
Establish IV access for power injection of gadolinium
Coach breath-holding; consider antispasmodic to reduce bowel motion
Position supine with a body phased-array coil and respiratory monitoring

Technique & Parameters

1.5T or 3T with body/torso phased-array coil and respiratory or navigator gating
Axial and coronal T2 (single-shot and fat-saturated) and axial in-/opposed-phase T1 (Dixon) for fat/iron
Diffusion-weighted imaging with ADC for lesion detection and characterization
MRCP: heavily T2-weighted thick-slab radial and 3D thin-section acquisitions of the biliary tree
Dynamic 3D fat-suppressed T1 (VIBE/LAVA) pre-contrast and arterial, portal venous, and delayed phases after 0.1 mmol/kg gadolinium
Hepatobiliary phase at 20 minutes when using gadoxetate for lesion characterization
Slice thickness 3-5 mm; timing arterial phase by bolus tracking or test bolus

Systematic Review

Assess overall liver morphology, signal, fat/iron content, and surface contour
Characterize each focal liver lesion across all sequences and dynamic phases
Trace the intra- and extrahepatic biliary tree and pancreatic duct on MRCP
Evaluate the pancreas for masses, ductal dilatation, and parenchymal signal
Assess both kidneys for masses, complex cysts, and enhancement
Characterize the adrenals for signal drop-out on opposed-phase imaging
Review the spleen, bowel, mesentery, and vasculature (portal/hepatic/splenic veins)
Inspect lymph nodes, ascites, and the imaged lung bases and skeleton

Key Findings & Significance

Arterial hyperenhancement with washout and capsule in a cirrhotic liver indicates HCC (LI-RADS)
Progressive nodular discontinuous peripheral enhancement following blood pool indicates hemangioma
Central scar with hepatobiliary-phase iso/hyperintensity favors focal nodular hyperplasia
Signal loss on opposed-phase imaging indicates intracellular fat (adenoma or adrenal adenoma)
Biliary ductal dilatation to an abrupt cutoff suggests obstructing stone or stricture/tumor
Cystic pancreatic lesion communicating with a dilated main duct suggests IPMN
Restricted diffusion in a solid mass raises concern for malignancy

Differential Considerations

Arterial-enhancing liver lesion: HCC, FNH, adenoma, hypervascular metastasis, transient hepatic attenuation difference
Cystic liver lesion: simple cyst, biliary hamartoma, hydatid, abscess, biliary cystadenoma/carcinoma
Pancreatic mass: adenocarcinoma, neuroendocrine tumor, focal pancreatitis, metastasis
Pancreatic cyst: IPMN, mucinous cystic neoplasm, serous cystadenoma, pseudocyst
Renal mass: clear cell/papillary RCC, oncocytoma, angiomyolipoma (fat-containing), complex cyst
Adrenal mass: adenoma (signal drop-out), pheochromocytoma, metastasis, myelolipoma, carcinoma

Pearls & Pitfalls

Chemical-shift signal drop-out reliably indicates microscopic fat (adenoma, adrenal adenoma, HCC)
Gadoxetate hepatobiliary phase distinguishes FNH (retains) from adenoma/metastasis (does not)
Transient severe motion during gadoxetate arterial phase can mimic or obscure lesions
Correlate DWI with ADC to avoid T2 shine-through misinterpretation
MRCP overestimates strictures if flow/pulsation artifact is present; use multiple projections
Do not mistake pseudolesions (perfusion changes, focal fat/sparing) for true lesions
Iron deposition lowers signal on in-phase relative to opposed-phase (reverse of fat)

Structured Report

State indication, technique, contrast agent/dose, and comparison studies
Report liver size, fat/iron content, and characterize each focal lesion with dynamic behavior
Apply LI-RADS categorization for at-risk patients
Describe biliary and pancreatic ductal caliber and any obstructing lesion
Report renal, adrenal, splenic, nodal, and vascular findings
Impression: specific characterization or ranked differential with management recommendation
Recommend biopsy, follow-up interval, or MDT referral as appropriate

References

ACR LI-RADS v2018 for HCC characterization
ACR Appropriateness Criteria: liver lesion characterization; suspected pancreatic disease
ESGAR/European consensus guidelines on pancreatic cystic neoplasms
RadioGraphics reviews on chemical-shift imaging and hepatobiliary contrast agents
Fujita/standard abdominal MRI protocols; ACR-SAR MRCP practice parameters

Educational clinical decision support only. Protocols vary by institution and equipment; always confirm with a qualified radiologist and local guidelines before clinical use.

MRI Abdomen with Contrast

📋 Indications

⛔ Contraindications & Cautions

🧑‍⚕️ Patient Preparation

⚙️ Technique & Parameters

🔎 Systematic Review

🩻 Key Findings & Significance

🧠 Differential Considerations

💡 Pearls & Pitfalls

📝 Structured Report

📚 References